Boehringer

ClinicalAugust 6, 2026

Boehringer Ingelheim's BI 764532 Trial in Advanced Neuroendocrine Cancers Underway

Boehringer Ingelheim is conducting a trial (DAREON™-7) to evaluate the tolerability of BI 764532 combined with chemotherapy in advanced neuroendocrine cancer patients.

Sponsor company

Mechanism of action

Recent signals(9)

Boehringer Ingelheim's BI 764532 Trial in Advanced Neuroendocrine Cancers Underway

Boehringer Ingelheim's BI 764198 Trial Focuses on Safety and Pharmacokinetics

Boehringer Ingelheim Initiates Dose-Exploration Study of BI 1831169 with Anti-PD1 in Advanced Cancer

Boehringer Ingelheim Study on HER2-Altered Metastatic Breast Cancer Treatment Patterns

Boehringer Ingelheim's Nerandomilast Trial for Lung Fibrosis in Autoimmune Diseases

Boehringer Ingelheim's Nerandomilast Trial for Fibrosing ILD Shows Potential for Disease Progression

Boehringer Ingelheim's BI 764198 Trial Examines Formulation Impact on Bioavailability

Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients

Boehringer Ingelheim Initiates Phase 1 Study of BI 1831169 in Advanced Solid Tumors

Upcoming milestones

Related catalysts

Indications

Therapeutic areas

Get signals before the market moves